. Author manuscript; available in PMC: 2020 Sep 30.

Published in final edited form as: Arch Biochem Biophys. 2019 Aug 22;673:108078. doi: 10.1016/j.abb.2019.108078

Table 3.

Inhibitors of human CYP3A7 activity.

Inhibitor	Substrate reaction	Reference
Triacetyloleandomycin	N-demethylation	[19]
α-naphthoflavone	Imipramine N-demethylation	[19]
Troleandomycin	all-trans-retinoic acid 4-hydroxylation	[62]
Estradiol	Carbamazepine 10,11-epoxidation	[32]
Triazolam	Testosterone 6β-hydroxylation	[68]
Amprenavir	Testosterone 6β-hydroxylation	[36]
Indinavir	Testosterone 6β-hydroxylation	[36]
Nelfinavir	Testosterone 6β-hydroxylation	[36]
Ritonavir	Testosterone 6β-hydroxylation	[36]
Saquinavir	Testosterone 6β-hydroxylation	[36]
Azamulin	7-benzyloxy-4-trifluoromethylcoumarin	[88]
Ketoconazole	7-benzyloxy-4-trifluoromethylcoumarin	[87,88]
Δ⁹-tetrahydrocannabinol	Diltiazem N-demethylation	[76]
Cannabidiol	Diltiazem N-demethylation	[76]
Cannabinol	Diltiazem N-demethylation	[76]
Olivetol	Diltiazem N-demethylation	[76]
Hop-Containing products	Dibenzylfluorescein, 7-ethoxy-3-cyanocoumarin, 7-methoxy-4-trifluoromethylcoumarin	[89]
West African medicinal and food plants	Dibenzylfluorescein	[90]
Melatonin products	NA	[91]
Astemizole Cisapride Clotrimazole Cyclosporine A Erythromycin Ketoconazole Mibefradil Midazolam Nicardipine Nifedipine Nimodipine Terfenadine Troleandomycin Verapamil	7-benzyloxy-4-trifluoromethylcoumarin O-dealkylation	[92]

NA, not available.